How Nitrosamine Impurities Affect Your Blood Pressure Medicine

How nitrosamine affects blood pressure medicine

Guest Author: Phil Koerner, PhD. The U.S. Food and Drug Administration (USFDA) and The European Medicines Agency (EMA) have set legally-binding limits for nitrosamine impurities in sartan blood pressure medicines. Continue Reading

Sartan Drugs Have Been Deemed in Shortage by the FDA

sartan drugs

The US Food and Drug Administration (FDA) is warning that there is a shortage of drugs that is used by millions to treat high blood pressure. The drugs known as Continue Reading

LC-MS/MS Method for Determination of NDMA and NDEA in Valsartan

Valsartan

By: Philip J. Koerner, Ph.D. – Global Industry Manager – Pharmaceutical The Korea Food and Drug Administration (KFDA), in cooperation with SCIEX Korea, has recently published an official LC-MS/MS method using Continue Reading